Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

Clinical Results - Autologous Transplantation Poster II

Sunday, December 7, 2008: 6:00 PM-8:00 PM
Hall A (Moscone Center)
Transplanted CD34+ Cell Dose Is Associated with Long-Term Platelet Count Following Autologous Hematopoietic Stem Cell Transplant in Patients with Non-Hodgkin’s Lymphoma and Multiple Myeloma

Patrick J. Stiff, MD1, Ivana NM Micallef2*, Auayporn P. Nademanee3, Edward A. Stadtmauer, MD4, Richard Thomas Maziarz, MD5, Brian J. Bolwell, MD6, Gary Bridger, PhD7*, Gary Calandra, MD, PhD8, Jennifer Angell, MS7* and John F. DiPersio, MD, PhD9

1Loyola Univ. Med. Ctr., Maywood, IL
2Mayo Clinic, Rochester, MN
3City of Hope National Medical Center, Duarte, CA
4Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA
5OR Health Sciences Univ., Portland, OR
6Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
7Genzyme, Cambridge, MA
8Genzyme, Cresco, PA
9School of Medicine, Washington University, Saint Louis, MO

BuCy Provides Equivalent Outcomes to VCyTBI as Conditioning Prior to Auto-SCT in Patients with Relapsed/Refractory NHL and Is a Valuable Option in Older (≥60 years) Patients

Shannon L Smiley, MD*, Theresa Hahn, PhD, Wei Tan, MS*, Gregory Wilding, PhD*, Minoo Battiwalla, MD* and Philip L. McCarthy Jr., MD*

Roswell Park Cancer Institute, Buffalo, NY

Prognosis Value of [18f] FDG-PET Prior Versus after Autologous Stem Cells Transplantation in High Grade Non-Hodgkin’s Lymphoma

Virginie Roland1*, Caroline Bodet Milin2*, Anne Moreau3*, Thomas Gastinne3*, Beatrice Mahe3*, Viviane Dubruille3*, Hervé Maisonneuve4*, Nadine Morineau5*, Philippe Moreau6*, Henri Jardel7*, Lucie Planche8*, Philippe Moreau9*, Jean-Luc Harousseau10, Françoise Kraeber bodere2* and Steven Le Gouill, MD, PhD1*

1Haematology, CHU Nantes, Nantes, France
2Nuclear medecine, CHU de Nantes, Nantes, France
3CHU de Nantes, Nantes, France
4Hematology, CHD Roche sur yon, Roche sur Yon, France
5Hematology department, Centre Catherine de Sienne, Reze, France
6Hematology department, Ch de Lorient, Lorient, France
7Hematology department, CH chubert de Vannes, Vannes, France
8Cellule de Promotion à la recherche clinique, CHU Hotel-Dieu, Nantes, France
9Hematology Department, Hopital de Nantes, Nantes, France
10Hôpital Hôtel Dieu, Nantes, France

The Role of FDG-PET in Hodgkin Lymphoma S/P Autologous Hematopoietic Cell Transplant (HCT) as a Predictor of Outcome

Neel B. Shah, MD, Mohamed Farhat, M.D.*, Arti Lakhani, M.D.*, Daniel Mcfarland, D.O.*, Parameswaran Venugopal, M.D.*, Stephanie A Gregory, M.D.*, Jamile Shammo, M.D.*, John Maciejewski, M.D.*, Hande Tuncer, M.D.* and Henry C Fung, M.D.*

Hematology, Rush University Hospital, Chicago, IL

Outcome of Transplant-Eligible Patients with Hodgkin Lymphoma with An Inadequate Response to Second Line Chemotherapy with Gemcitabine, Dexamethasone, Cisplatin (GDP)

Tara Seshadri, MBBS1, Christine Massey2*, Noemi Puig1*, Armand Keating, MD1, Michael Crump, MD1 and John Kuruvilla, MD3

1Princess Margaret Hospital, Toronto, ON, Canada
2Biostatistics, Princess Margaret Hospital, Toronto, Canada
3The Princess Margaret Hospital, Toronto, ON, Canada

Early Pre/Post Fluoro-Deoxyglucose Positive Emission Tomography (PET) Does Not Predict Outcome of Patients Undergoing Hematopoietic Stem Cell Transplantation in Hodgkins Disease and Non-Hodgkins Lymphoma

Jeanne Palmer, MD1, Timothy Goggins, MD2*, Gloria Broadwater3*, Nelson J. Chao, MD3, John Chute, MD3, R. E. Coleman, MD4*, Keith M Sullivan, MD3, Gwynn Long, MD3*, Cristina Gasparetto, MD3*, Anne Beaven, MD3* and David Rizzieri, MD3*

1Division of Neoplastic Diseases, MCW & Froedtert Clinical Cancer Center, Milwaukee, WI
2Hematology/Medical Oncology, St Elizabeth's Hospital, Appleton, WI
3Duke University Medical Center, Durham, NC
4Radiology, Duke University Medical Center, Durham, NC

HIV Status Does Not Affect the Outcome of Autologous Stem Cell Transplantation (ASCT) for B Cell Non Hodgkin Lymphoma (NHL)

Amrita Krishnan, MD, FACP, John Zaia MD*, Joseph Alvarnas MD*, Neil Kogut MD*, Ricardo Spielberger MD*, Michelle Wardlow RN*, Nicole Tsai MS*, Tanya Paris BS* and Stephen J Forman MD*

City of Hope National Medical Center, Duarte, CA

Impact on Progression Free Survival of Autologous Stem Cell transplantation after Consolidation with Alemtuzumab in Chronic Lymphocytic Leukemia

Marco Montillo1, Francesca Ricci1*, Alessandra Tedeschi1*, Sara Miqueleiz1*, Giovanni Grillo1*, Eleonora Vismara1*, Antonino Greco1*, Silvio Veronese2* and Enrica Morra1*

1Department of Hematology, Niguarda Ca' Granda Hospital, Milano, Italy
2Department of Pathology, Niguarda Ca' Granda Hospital, Milano, Italy

15 Year Follow-up of ABMT for NHL: Surprisingly Favorable Outcome for Younger Adults

Hien Duong*, Lisa Rybicki*, Steven Andresen*, Edward Copelan, Robert Dean, Matt Kalaycio, Brad Pohlman, Ronald Sobecks, John Sweetenham*, Josephine Chan*, Shawnda Sungren* and Brian Bolwell

Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Length of Stay among Patients Undergoing Autologous Stem Cell Transplantation for Lymphoma:Predictive Factors and Prognostic Effect

Anuj Mahindra, Brian Bolwell, Lisa Rybicki*, Matt Kalaycio, Ronald Sobecks, Steve Andresen*, Brad Pohlman, John Sweetenham*, Edward Copelan and Robert Dean

Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Long Term Molecular Remissions after Autologous Haematopoietic Stem Cell Transplant in Follicular Lymphoma

Séverine Lissandre, MD1*, Patrick Vourch, MD2*, Isabelle Desbois, MD3*, Lotfi Benboubker, MD1*, Caroline Dartigeas, MD1*, Martine Delain, MD1*, Delphine Senecal, MD1*, Philippe Colombat, MD, PhD1 and Emmanuel Gyan, MD1*

1Service d'Hématologie et Thérapie Cellulaire, CHU de Tours, Tours, France
2Laboratoire de Biochimie et Biologie moléculaire, CHU de Tours, Tours, France
3Laboratoire de Thérapie Cellulaire, Etablissement Français du Sang, Tours, France

Superior Survival in Non-Hodgkin Lymphoma Following Autologous Stem Cell Transplantation with Intravenous Busulfan, Cyclophosphamide, and Etoposide

Robert Dean1, Lisa Rybicki2*, Brad Pohlman1, John William Sweetenham1, Stephen Smith1, Edward Copelan1, Ronald Sobecks1, Matt Kalaycio1, Steven Andresen1*, Shawnda Sungren1* and Brian J. Bolwell, MD1

1Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
2Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH

Red Marrow Dosimetry and Stem Cell Reinfusion in High Dose 90 Y - Ibritumomab Tiuxetan

Anna Vanazzi1*, Daniele Laszlo1*, Marta Cremonesi2*, Chiara Maria Grana2*, Stefano Papi2*, Alessandra Alietti1*, Sarah Jayne Liptrott1*, Liliana Calabrese1*, Giovanni Paganelli2* and Giovanni Martinelli1

1Hematoncology, European Institute of Oncology, Milano, Italy
2Nuclear Medicine, European Institute of Oncology, Milano, Italy

Complete Remission on 18F-FDG-PET Prior to Autologous Stem Cell Transplantation Predicts Superior Event Free Survival of Patients with Relapsed or Refractory Hodgkin Lymphoma

Stefan Peinert1, Rosemary Hoyt2*, Jeffrey Szer3, John F. Seymour1*, H. Miles Prince1*, Andrew W Roberts2, Luigi Rigacci4*, Andrew Grigg2 and David S. Ritchie1*

1Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia
2Med. Onc./Hem., Royal Melbourne Hospital, Melbourne, Australia
3Clinical Haematology & BMT Service, The Royal Melbourne Hospital, Parkville, Australia
4Hematology, Azienda Ospedaliero Universitaria Careggi, Florence, Italy

Impact of Autologous Stem Cell Transplantation and/or Rituximab on Outcome of Patients with Relapsed Follicular Lymphoma- Retrospective Analysis of 2 Randomized Trials of the German Low Grade Lymphoma Study Group (GLSG)

Oliver Weigert1*, Atakan Uysal1*, Bernd Metzner2, Michael Pfreundschuh3, Norbert Schmitz4*, Hannes Wandt5*, Christian Peschel6*, Eva Hoster1*, Michael Unterhalt1*, Wolfgang Hiddemann1* and Martin Dreyling1

1Department of Internal Medicine III, University Hospital of Munich, Großhadern, Munich, Germany
2Department of Hematology/Oncology, University Hospital Oldenburg, Oldenburg, Germany
3Department of Internal Medicine I, University Hospital Homburg, Homburg, Germany
4Department of Hematology & Stem cell transplantation, Asclepios Clinic St. Georg, Hamburg, Germany
5Medical Department 5, University Hospital Nuernberg Nord, Nuernberg, Germany
6Department of Hematology/Oncology, University Hospital Klinikum Rechts der Isar, Munich, Germany

Prolonged PFS after Autologous Stem Cell Transplantation in Follicular Lymphoma Patients: A Long-Term Retrospective Study

Violaine Safar1*, Thomas Gastinne2*, Noel Milpied, MD3*, Hervé Maisonneuve4*, Nadine Morineau5*, Viviane Dubruille6*, Beatrice Mahé1*, Philippe Moreau7*, Henri Jardel8*, Lucie Planche9*, Philippe Moreau10*, Jean-Luc Harousseau11 and Steven Le Gouill, MD12*

1Haematology Department, CHU de Nantes, Nantes, France
2CHU de Nantes, Nantes, France
3Hématologie, CHU de Bordeaux, Bordeaux, France
4Hematology, CHD Roche sur yon, Roche sur Yon, France
5Hematology department, Centre Catherine de Sienne, Reze, France
6Hopital Hotel Dieu, Nantes, France
7Hematology department, Ch de Lorient, Lorient, France
8Hematology department, CH chubert de Vannes, Vannes, France
9Cellule de Promotion à la recherche clinique, CHU Hotel-Dieu, Nantes, France
10Hematology Department, Hopital de Nantes, Nantes, France
11Hôpital Hôtel Dieu, Nantes, France
12Haematology, CHU Nantes, Nantes, France

High Dose Therapy and Autologous Stem Cell Transplantation Still Improves Progression Free Survival in First Relapse for DLBCL in the Rituximab Era: A Study Using Patients as Their Own Controls

Anna Sureda*, Carme Canals*, Nicolas Mounier*, Roberto Foa*, Eulogio Conde*, Johan Maertens*, Alessandro Rambaldi, Tamas Masszi*, Charles Crawley, Gordon Cook*, Michel Attal*, Michael Pfreundschuh*, Jean-Luc Harousseau* and Christian Gisselbrecht*

for the Lymphoma Working Party of the EBMT, Barcelona, Spain

Fludarabine, but Not Mitoxantrone, Increases the Risk of a Poor Stem Cell Harvest and Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia (tMDS/AML) after Autologous Stem Cell Transplantation (ASCT) in Patients with Follicular Lymphoma (FL)

Jason Waterman*, Lisa Rybicki*, Brian Bolwell, Ronald Sobecks, Brad Pohlman, Edward Copelan, John Sweetenham*, Robert Dean, Josephine Chan* and Matt Kalaycio

Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Achievement a Negative 18-FDG/PET Status at the End of Procedure by Tailored Treatment According Pre-Transplantation Pet Status in Lymphomas Improve 5 Years-OS and EFSClinically Relevant Abstract

Dominique Bordessoule1, Benoit Marin2*, Stéphane Girault3*, Fredericka Bompart4*, Julie Abraham5*, Natacha Dmytruck6*, Arnaud Jaccard7*, Jacques Monteil8* and Pascal Turlure9*

1Service D'hematologie Et De Thérapie Cellulaire, CHU Dupuytren, Limoges, France
2Université de limoges, unité de RC et biostatistiques, 87042, France
3Service d'Hématologie Clinique, CHU Dupuytren, Limoges, France
4Service D'hématologie Et De Thérapie Cellulaire, CHU Dupuytren, Limoges, France
5Service D'hematologie Et De Therapie Cellulaire, CHU Dupuytren, Limoges
6Service D'hematologie Et De Therapie Cellulaire, CHU Dupuytren, Limoges, France
7Department of Hematology, University Hospital, Limoges, France
8Service De Medecine Nucleaire, CHU Dupuytren, Limoges, France
9Hematology, CHU de Limoges, Limoges, France

Phase I/II Trial of a Novel Gemcitabine and Vinorelbine-Containing Conditioning Regimen in Autologous Hemotopoietic Cell Transplantation for High-Risk Recurrent and Refractory Hodgkin Lymphoma

Sally Arai, MD, Renee Letsinger*, Laura Johnston*, Ginna Laport*, Robert Lowsky*, David Miklos*, Judith Shizuru*, Wen-Kai Weng*, Ruby Wong*, Philip Lavori*, Karl Blume*, Robert Negrin* and Sandra Horning*

Bone Marrow Transplant, Stanford University Medical Center, Stanford, CA

*signifies non-member of ASH